Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Secutrelvir - Shionogi

Next Previous
Drug Profile

Secutrelvir - Shionogi

Alternative Names: S-892216

Latest Information Update: 03 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shionogi
  • Class Acetonitriles; Antivirals; Azetidines; Chlorinated hydrocarbons; Chlorobenzenes; Cyclobutanes; Fluorinated hydrocarbons; Fluorobenzenes; Pyridines; Pyrimidines; Small molecules; Spiro compounds
  • Mechanism of Action Coronavirus 3C protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III COVID 2019 infections

Most Recent Events

  • 25 Aug 2026 Phase-III clinical trials in COVID-2019 infections (In adolescents, In adults, In the elderly) in Japan (PO) (NCT07743580)
  • 06 Aug 2026 Shionogi plans a phase III trial for COVID-2019 infections (In adolescents, In adults, In the elderly) in the US, Bulgaria and Japan (PO, Tablet), in August 2026 (NCT07743580)
  • 05 Aug 2026 Shionogi initiates enrolment in the phase III trial for COVID-19 infections (In adolescent, In adults, In elderly) in Japan (PO, Tablet) (NCT07746544)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top